


In the Claims

Claims 1-24 (canceled)

25. (currently amended) A compound represented by C:



wherein

m is 0, 1, 2, or 3;

n is 0, 1, 2, or 3;

p is 1, 2, or 3;

W represents CH₂, or O [[, or NR]];

X represents S [[or O]];

Y represents CR' [[, or N]];

R represents H or alkyl;

R' represents H, alkyl, or halogen;

R₁ represents H or alkyl;

R₂ represents aryl [[, or heteroaryl]];

R₃ represents H or alkyl;

R₄ represents H or alkyl;

R₅ represents H or alkyl;

R₁ and R₄ may be connected through a covalent bond;

[[R₃ and R₄ may be connected through a covalent bond;]]

R₄ and R₅ may be connected through a covalent bond; [[or -N(R₄)(R₅) represents 4-morpholinyl;]] and

the stereochemical configuration at a stereocenter in a compound represented by C is R, S, or a mixture thereof.

26. (canceled)

27. (canceled)

28. (canceled)

29. (original) The compound of claim 25, wherein n is 1 or 2; and p is 2.

30. (original) The compound of claim 25, wherein R' represents H.

31. (currently amended) The compound of claim 25, wherein R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, or 2-fluorophenyl [[, or 5-chlorobenzo[b]thiophen-3-yl]].

32. (canceled)

33. (canceled)

34. (canceled)

35. (currently amended) The compound of claim 25, wherein [[X represents S; Y represents CR'; W represents CH₂ or O;]] n is 1 or 2; p is 2; and R' represents H.

36. (currently amended) The compound of claim 25, wherein [[X represents S; Y represents CR'; W represents CH₂ or O;]] n is 1 or 2; p is 2; R' represents H; and R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, or 2-fluorophenyl [[, or 5-chlorobenzo[b]thiophen-3-yl]].

Claims 37-44 (canceled)

45. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

46. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
47. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
48. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
49. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
50. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
51. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
52. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
53. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
54. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

55. **(currently amended)** The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

56. **(currently amended)** The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

57. **(currently amended)** The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound is a single stereoisomer.

58. **(currently amended)** A formulation, comprising a compound of claim [[1, 17,]] 25 [[, or 37]]; and a pharmaceutically acceptable excipient.

Claims 59-105(**canceled**)